No way! But... [Design Issues]

posted by wienui  – Germany/Oman, 2019-12-07 05:01 (1158 d 11:43 ago) – Posting: # 20955
Views: 5,441

(edited by wienui on 2019-12-07 06:47)

Dear all,

❝ So here two answers - theoretically there is no problem to use all data, but regulatory authorities can bann you for it. (IMHO)


I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

Best regards,
Osama

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
17 visitors (0 registered, 17 guests [including 5 identified bots]).
Forum time: 16:44 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5